Bausch Health Companies (BHC) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Teva Pharmaceutical Industries (TEVA) has outperformed Bausch Health Companies (BHC) over the past year, gaining 95.2% versus a loss of 3.8%. Over five years, TEVA leads with a +304.8% price change compared with -78.4% for BHC. Teva Pharmaceutical Industries is the larger company by market cap ($45.78 billion vs $2.26 billion), about 20.3 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.4x vs 12.7x for Teva Pharmaceutical Industries).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | TEVA |
|---|---|---|
| Share price | $6.04 | $39.25 |
| Market cap | $2.26B | $45.78B |
| 1-day change | -1.79% | +0.18% |
| YTD return | -11.51% | +25.54% |
| 1-year return | -3.76% | +95.22% |
| 5-year return | -78.41% | +304.75% |
| P/E ratio (TTM) | — | 65.42 |
| Forward P/E | 1.44 | 12.70 |
| EPS (TTM) | $-2.95 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $17.26B |
| Revenue growth (YoY) | — | +4.32% |
| Net income (latest FY) | — | $1.41B |
| Gross margin | — | 51.79% |
| Operating margin | — | 12.50% |
| Net margin | — | 8.17% |
| 52-week high | $8.00 | $40.79 |
| 52-week low | $4.33 | $18.83 |
| Distance from 52-week high | -24.50% | -3.78% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +24.17% | +15.41% |
| Average volume | 3.24M | 5.29M |
| Shares outstanding | 373.99M | 1.17B |
| Employees | 20,300 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Teva Pharmaceutical Industries is about 20.3 times larger than Bausch Health Companies by market value ($45.78B vs $2.26B).
- TEVA has outperformed BHC by 99.0 percentage points over the past year.
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
BHC vs TEVA FAQ
Which is bigger, Bausch Health Companies or Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.78B compared with $2.26B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, BHC or TEVA?
TEVA returned +95.22% over the past 12 months, compared with -3.76% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Teva Pharmaceutical Industries in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.